We have established a dedicated oncology-focused commercial team in China to support the launch of products emerging from our innovative pipeline, building on the marketing, sales and market access experience gained from our prescription drug commercial operations.

As of mid-2023, an approximately 900-person oncology team is in place, covering over 3,000 oncology hospitals and over 33,000 oncology physicians in 30 provinces and municipalities in China.

Starting October 1, 2020, this team took on development and execution of all on-the-ground medical detailing, promotion and local and regional marketing activities for fruquintinib (Elunate^® in China). In January 2021, we launched our second approved therapy surufatinib (Sulanda^® in China).

Outside of China, we intend to commercialize our products, if approved, in the United States, Europe and other major markets through partnerships with leading biopharmaceutical companies.

Our prescription drugs business, conducted through our joint ventures (Shanghai Hutchison Pharmaceuticals and Hutchison Sinopharm) has a commercial network of about 2,300 prescription drug medical sales representatives, covering over 25,000 hospitals in over 330 cities and towns in China.

This large-scale, high-performing drug marketing and distribution platform has grown strongly and provides an important source of funding for our pipeline, and the infrastructure and expertise in operating and marketing pharmaceutical products in China.

Our commercial operations adheres to multi-national compliance standards and are adaptable to multiple therapeutic areas. This team has successfully marketed many third party products for multi-national corporations in China.